北京基因启明

Gene-Qi-Ming is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for solid tumors. The company leverages its proprietary G-TCR-T platform to identify and engineer high-affinity T-cell receptors targeting tumor-specific antigens. Its lead program, GQM-001, is a TCR-T therapy targeting HPV16 E7 for the treatment of HPV-positive cancers such as cervical and head and neck squamous cell carcinoma. Gene-Qi-Ming's pipeline also includes CAR-T and TCR-T candidates targeting NY-ESO-1 and Claudin 18.2, aiming to address significant unmet needs in oncology. The company is supported by prominent venture capital firms and maintains a strong focus on translational medicine.